vs
Citi Trends Inc（CTRN）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Citi Trends Inc的1.1倍（$219.9M vs $197.1M），Orthofix Medical Inc.净利率更高（-1.0% vs -3.5%，领先2.5%），Citi Trends Inc同比增速更快（10.1% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $767.0K），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -4.3%）
Citi Trends Inc是一家美国服装零售连锁品牌，主营折扣服饰商品，目标客群以非裔美国人为主，凭借高性价比的产品策略在美国本土折扣零售市场占据一席之地。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CTRN vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$197.1M
营收增速更快
CTRN
高出8.1%
2.0%
净利率更高
OFIX
高出2.5%
-3.5%
自由现金流更多
OFIX
多$16.1M
$767.0K
两年增速更快
OFIX
近两年复合增速
-4.3%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $197.1M | $219.9M |
| 净利润 | $-6.9M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | -3.7% | 0.2% |
| 净利率 | -3.5% | -1.0% |
| 营收同比 | 10.1% | 2.0% |
| 净利润同比 | 3.6% | 92.4% |
| 每股收益（稀释后） | $-0.86 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTRNOFIX
| Q4 25 | $197.1M | $219.9M | ||
| Q3 25 | $190.8M | $205.6M | ||
| Q2 25 | $201.7M | $203.1M | ||
| Q1 25 | $211.2M | $193.6M | ||
| Q4 24 | $179.1M | $215.7M | ||
| Q3 24 | $176.6M | $196.6M | ||
| Q2 24 | $186.3M | $198.6M | ||
| Q1 24 | $215.2M | $188.6M |
净利润CTRNOFIX
| Q4 25 | $-6.9M | $-2.2M | ||
| Q3 25 | $3.8M | $-22.8M | ||
| Q2 25 | $871.0K | $-14.1M | ||
| Q1 25 | $-14.2M | $-53.1M | ||
| Q4 24 | $-7.2M | $-29.1M | ||
| Q3 24 | $-18.4M | $-27.4M | ||
| Q2 24 | $-3.4M | $-33.4M | ||
| Q1 24 | $3.6M | $-36.0M |
毛利率CTRNOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率CTRNOFIX
| Q4 25 | -3.7% | 0.2% | ||
| Q3 25 | 1.8% | -8.3% | ||
| Q2 25 | 0.2% | -7.9% | ||
| Q1 25 | 0.6% | -25.2% | ||
| Q4 24 | -4.9% | -5.3% | ||
| Q3 24 | -14.1% | -9.6% | ||
| Q2 24 | -3.7% | -12.5% | ||
| Q1 24 | 1.8% | -15.6% |
净利率CTRNOFIX
| Q4 25 | -3.5% | -1.0% | ||
| Q3 25 | 2.0% | -11.1% | ||
| Q2 25 | 0.4% | -6.9% | ||
| Q1 25 | -6.7% | -27.4% | ||
| Q4 24 | -4.0% | -13.5% | ||
| Q3 24 | -10.4% | -13.9% | ||
| Q2 24 | -1.8% | -16.8% | ||
| Q1 24 | 1.7% | -19.1% |
每股收益（稀释后）CTRNOFIX
| Q4 25 | $-0.86 | $-0.05 | ||
| Q3 25 | $0.46 | $-0.57 | ||
| Q2 25 | $0.11 | $-0.36 | ||
| Q1 25 | $-1.70 | $-1.35 | ||
| Q4 24 | $-0.86 | $-0.76 | ||
| Q3 24 | $-2.21 | $-0.71 | ||
| Q2 24 | $-0.42 | $-0.88 | ||
| Q1 24 | $0.43 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $107.8M | $450.0M |
| 总资产 | $464.3M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTRNOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务CTRNOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益CTRNOFIX
| Q4 25 | $107.8M | $450.0M | ||
| Q3 25 | $113.2M | $442.5M | ||
| Q2 25 | $108.6M | $458.3M | ||
| Q1 25 | $113.2M | $458.3M | ||
| Q4 24 | $130.3M | $503.1M | ||
| Q3 24 | $136.6M | $525.9M | ||
| Q2 24 | $154.8M | $546.0M | ||
| Q1 24 | $157.7M | $570.3M |
总资产CTRNOFIX
| Q4 25 | $464.3M | $850.6M | ||
| Q3 25 | $457.4M | $832.6M | ||
| Q2 25 | $437.4M | $837.2M | ||
| Q1 25 | $462.8M | $823.1M | ||
| Q4 24 | $467.1M | $893.3M | ||
| Q3 24 | $506.7M | $867.9M | ||
| Q2 24 | $484.1M | $882.0M | ||
| Q1 24 | $518.7M | $906.0M |
负债/权益比CTRNOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.6M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $767.0K | $16.8M |
| 自由现金流率自由现金流/营收 | 0.4% | 7.6% |
| 资本支出强度资本支出/营收 | 4.0% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $11.9M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CTRNOFIX
| Q4 25 | $8.6M | $27.7M | ||
| Q3 25 | $3.9M | $12.4M | ||
| Q2 25 | $-11.0M | $11.6M | ||
| Q1 25 | $28.5M | $-18.4M | ||
| Q4 24 | $-18.4M | $23.7M | ||
| Q3 24 | $5.6M | $11.7M | ||
| Q2 24 | $-19.6M | $9.0M | ||
| Q1 24 | $23.3M | $-18.6M |
自由现金流CTRNOFIX
| Q4 25 | $767.0K | $16.8M | ||
| Q3 25 | $-1.7M | $2.5M | ||
| Q2 25 | $-13.1M | $4.5M | ||
| Q1 25 | $26.0M | $-25.1M | ||
| Q4 24 | $-20.4M | $15.2M | ||
| Q3 24 | $1.7M | $6.3M | ||
| Q2 24 | $-21.2M | $-360.0K | ||
| Q1 24 | $20.0M | $-29.1M |
自由现金流率CTRNOFIX
| Q4 25 | 0.4% | 7.6% | ||
| Q3 25 | -0.9% | 1.2% | ||
| Q2 25 | -6.5% | 2.2% | ||
| Q1 25 | 12.3% | -13.0% | ||
| Q4 24 | -11.4% | 7.0% | ||
| Q3 24 | 0.9% | 3.2% | ||
| Q2 24 | -11.4% | -0.2% | ||
| Q1 24 | 9.3% | -15.4% |
资本支出强度CTRNOFIX
| Q4 25 | 4.0% | 4.9% | ||
| Q3 25 | 2.9% | 4.8% | ||
| Q2 25 | 1.0% | 3.5% | ||
| Q1 25 | 1.2% | 3.5% | ||
| Q4 24 | 1.1% | 4.0% | ||
| Q3 24 | 2.2% | 2.7% | ||
| Q2 24 | 0.9% | 4.7% | ||
| Q1 24 | 1.5% | 5.6% |
现金转化率CTRNOFIX
| Q4 25 | — | — | ||
| Q3 25 | 1.01× | — | ||
| Q2 25 | -12.59× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 6.56× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTRN
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
